Setting our sights on infectious diseases

The Wellcome Centre for Anti-Infectives Research (WCAIR) invites you to join us in Dundee from 12-15 May 2019. The aim of the conference is to harness cross-disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate attrition rates for infectious diseases affecting low and middle income countries. Conference attendees will take home new ideas and technologies which have been demonstrated to work; applying them to diseases where challenges to drug discovery are hampering progress.

Watch Prof Ian Gilbert, Professor of Medicinal Chemistry, introduce the conference.

Topics to be discussed at the conference include:

  • Clinical development and connectivity to the preclinical situation
  • Combination therapy
  • Modern approaches to PK/PD studies
  • Development of clinical relevant screening cascades and assays
  • Early phase Drug Discovery- working smarter and faster

For the latest conference information follow @WCAIRDundee #SOSID2019 .

Download the latest programme

Social events will include a welcome reception at the School of Life Sciences on Sunday evening; Dinner at Discovery Point with the opportunity to visit the RRS Discovery; a reception at Dundee’s newest landmark, the V&A Dundee, with the opportunity to network while viewing the latest exhibition – Videogames: Design/Play/Disrupt.

Confirmed Speakers

We are pleased to announce new speakers have been added to the programme. They are

  • Sir Patrick Vallance, FRS, Government Chief Scientific Adviser (GCSA) and Head of the Government Science and Engineering (GSE) profession
  • Professor William Hope, University of Liverpool
  • Professor Jacquin Niles , Massachusetts Institute of Technology
  • Dr Jennifer Hermann, HelmHoltz Institute
  • Dr Srinivasa Rao, Novartis Institute for Tropical Diseases
  • Dr Ujjini Manjunatha, Novartis Institute for Tropical Diseases
  • Professor Frederick S. Buckner, University of Washington

Image showing the speakers at the WCAIR conference 2019

 

Thank you to

  • Bill and Melinda Gates Foundation
  • Drugs for Neglected Diseases initiative, DNDi
  • Medicines for Malaria Venture, MMV
  • Novartis

for their generous sponsorship which has allowed us to provide travel bursaries for 18 researchers attending from low and middle income countries

Thank you to RxNet for helping to publicise the conference